The pandemic of COVID-19 virus caught the world unprepared. The reported deaths by the virus in the USA are now almost two times the number of US servicemen that died in the Viet Nam conflict---over 90,000 dead. This tragedy occurred in just three months. Effective treatment is not immediately evident. We propose stress proteins and in particular heme oxygenase 1 (HO-1, Hsp32) may play a role in the virus' pathological impact and as a therapeutic modality.

Conditions associated with a higher morbidity and mortality from COVID-19 infection are characteristics of the metabolic syndrome (insulin resistance, diabetes, obesity, hypertension, cardiovascular disease), old age, male gender, and mechanical ventilator support. Pertinently, these groups generally have lower intracellular stress protein levels including low HO-1. Low intracellular stress proteins make these populations vulnerable to stress from whatever type of assault, whether infection, trauma, or poison (De Maio and Hightower [@CR9]) (Hooper and Hooper [@CR18]). Individuals with metabolic syndrome and insulin resistance have low-grade inflammation that can set a milieu for COVID-19 infection to trigger a cytokine storm, a common near-terminal event with multi-organ damage seen in COVID infection. (Mehta et al. [@CR29]) Indeed, knocking out HO-1 genes in animal models increases lung damage caused by sepsis. (Chen et al. [@CR8]) Conversely, raising HO-1 and other stress reduces inflammation and improves insulin resistance and in animal models lengthens life span. (Hooper et al. [@CR20])

A peculiarity of COVID-19 infection may be blockade of heme production. (Wenzhong and Li [@CR39]) The cytoprotective properties of HO-1 are largely the result of HO-1 enzymatic cleaving of heme into biliverdin, ferrous iron, and carbon monoxide. These products limit inflammation and oxidative stress, protecting tissues. (Fujioka et al. [@CR14]; Takeda et al. [@CR37]) COVID-19 blockade of heme synthesis could limit the HO-1 stress tolerance function, contributing to host fragility. Notably, in the Han Chinese population in Taiwan, protection from SARS corona viral infection is associated with a higher HO-1 expression in the HO-1(−497A/\*) genotype. (Hsieh et al. [@CR22])

Older individuals are at particular risk of dying from COVID-19. Recent data on 5700 hospitalized COVID-19 patients in New York City observed that the mortality of patients on mechanical ventilation over age 65 was 97.2%, compared with 76.4% for those 18--65. (Richardson et al. [@CR33]) In an attempt to understand age-related COVID-19 mortality, Abouhashem and coworkers studied antioxidant genes including regulators of HO-1 in human alveolar tissue. They found a pronounced reduction of HO-1-inducing genes in tissue from older individuals relative to young. The authors proposed that the low HO-1 state in the older subjects might contribute to susceptibility to a hyper-inflammatory state that results in cytokine storm. (Abouhashem et al. [@CR1]) Previous studies in rodents reported a reduced HO-1 response to heat- or alcohol-induced stress as animals aged. (Bloomer et al. [@CR6]; Patriarca et al. [@CR32])

HO-1 has anti-viral activity. In animal studies, HO-1 induction by cobalt protoporphyrin or overexpression of its upstream regulatory gene, Nrf2, is effective in combating Hepatitis C and B viruses, Ebola virus, human immunodeficiency virus, dengue virus, Zika virus, and human respiratory syncytial virus. (El Kalamouni et al. [@CR10]; Espinoza et al. [@CR12]) It is not surprising that some of these viruses turn off the production of HO-1, consistent with the stress protein being a threat to the virus, or that the host, in an attempt to resist viral commandeering of its protein synthesis, shuts down protein production, including stress proteins. (Hooper et al. [@CR19]) Gene overexpression and cobalt protoporphyrin are not presently available clinically. However, hemin, a substrate for HO-1 obtained from the breakdown of red blood cells, is FDA approved for treatment of porphyria and is effective in blocking Zika viral replication. (Huang et al. [@CR23]) To our knowledge, hemin has not been used to treat COVID-19.

The high mortality associated with mechanical ventilation in older COVID-19 patients prompts asking "does ventilation itself contribute to injury and poor outcomes?" One of the lessons learned from the New York City experience was to withhold intubation for as long as possible. Indeed, ventilator lung injury is well known in the anesthesia surgical fields. Specifically, cytokine activation and generation of reactive oxygen species contribute to a vicious cycle (Fig. [1](#Fig1){ref-type="fig"}) that can end in systemic inflammation and multi-organ failure. (Belperio et al. [@CR5])Fig. 1Cytokine, endotoxin, and microbial agents released from the acute lung injury/acute respiratory distress syndrome (ALI/ ARDS) lung during injurious mechanical ventilation. Mechanical ventilation--associated and mechanical ventilation--induced lung injury causes impairment of the integrity of the alveolar-capillary membrane and results in augmented cytokine release leading to translocation of cytokines/endotoxin/microbial agents from the lung to the circulation, contributing to systemic inflammation and a multi-organ dysfunction syndrome. With permission (Belperio et al. [@CR5])

Two volatile anesthetics (isoflurane and sevoflurane) raise heme oxygenase and aid in cytoprotection during heart and liver surgery. (Brioni et al. [@CR7]; Schmidt [@CR34]) Interestingly, long-term isoflurane helps recovery and reduces bronchospasm from herpes simplex pneumonia. (Hornuss et al. [@CR21]) Sevoflurane improved pulmonary mechanics and gas exchange in a case series of infants with severe bronchiolitis and acute respiratory distress syndrome. (Nacoti et al. [@CR31]) In short, a controlled clinical trial of isoflurane or sevoflurane when intubated COVID-19 patients are sedated is warranted.

Reports across the world repeatedly observe that sickest patients are male. Data from New York City found that among hospitalized COVID-19 patients under age 60, the death rate of women was one-third that of men. Among those over 60, the death rate of women was two-thirds that of men. (Richardson et al. [@CR33]) Why the gender difference? Studies suggest that double X chromosomes allow females to carry twice the TLR7 gene than carried in males. TLR7 expressed in immune cells recognizes single-strand RNA viruses and promotes production of antibodies against the virus, resulting in double protection for women. (Laffont et al. [@CR26]) In addition to the double X hypothesis, hormonal differences between the genders may have a role in protecting females. Women have more stress proteins in their heart and less cardiovascular disease than men. (Knowlton and Korzick [@CR25]) Estrogen administration reduces heart failure in postmenopausal women with failing hearts. (Lindenfeld et al. [@CR28]) Relevantly, estradiol administration raised intracellular HO-1 and reduced inflammation, edema, and cell death in a rodent model of trauma-hemorrhage-induced lung injury. A specific HO-1 enzyme inhibitor blocked protective effects of estrogen against injury to the lung. (Hsu et al. [@CR38]) It is no surprise that in the past month a Hungarian researcher, Zsuzsanna Suba, recommended that exogenous estrogen administration be given to COVID-19 victims, male or female. (Suba [@CR36]) In our own experience, estrogen administration was effective in a hypotensive woman with staphylococcal toxic shock. She was not recovering after a week of conventional therapy until she received an injection of estradiol. (Hooper [@CR17])

A recent observation is that the prevalence of people who currently smoke cigarettes admitted for COVID-19 was low compared with the prevalence of smoking in the local general population. In China, current smokers had 1/4th the prevalence of COVID-19 hospitalizations as the general population smoking prevalence. In France, the smoker rate was 5% of COVID-19 admissions compared with a 25% smoker rate for the general French population. (Geier and Geier [@CR15]) Relevantly and importantly, cigarette smoke is associated with increased HO-1 induction in lung fibroblasts and vascular endothelial cells. (Baglole et al. [@CR4]; Yang et al. [@CR40])

Therapeutic medications and herbs that raise HO-1 have anti-viral activity and are readily available. These include HMG CoA reductase inhibitors (statins) (Fedson et al. [@CR13]; Lee et al. [@CR27] melatonin (Anderson and Reiter [@CR3]; Shi et al. [@CR35]), curcumin (Aggarwal et al. [@CR2]; Moghadamtousi et al. [@CR30]), and resveratrol (El-hawary et al. [@CR11]). Resveratrol is a stilbene, and pterostilbene is better absorbed than resveratrol. Thus, pterostilbene is the preferred stilbene (Kapetanovic et al. [@CR24]). These agents have a good safety profile and are inexpensive. Additionally, a recently proposed hypothesis is to use hyperbaric oxygen therapy (HBOT) to improve oxygenation in COVID-19 patients. (De Maio and Hightower [@CR9]) HBOT raises HO-1 levels and is cytoprotective. (Godman et al. [@CR16])

The ongoing pandemic may be slowed by therapies that are widely available. Appropriate trials should be done to find preventive and/or therapeutic products for COVID-19 infection.
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